{"contentid": 488260, "importid": NaN, "name": "Russia\u00e2\u0080\u0099s pharma to accelerate expansion into Central and South America", "introduction": "Russia is accelerating its expansion in the pharmaceutical market of Central and South American states by localization of a number of drugs within their territories, according to recent statements by representatives of some leading Russian drugmakers and pharma analysts, reports The Pharma Letter\u00e2\u0080\u0099s local correspondent.", "content": "<p>Russia is accelerating its expansion in the pharmaceutical market of Central and South American states by localization of a number of drugs within their territories, according to recent statements by representatives of some leading Russian drugmakers and pharma analysts, reports The Pharma Letter&rsquo;s local correspondent.</p>\n<p>One such drugmaker is Geropharm, which has recently announced plans to start the production of insulin in Venezuela.&nbsp;</p>\n<p>The launch of the new production will be part of a long-term agreement, which was signed by the company with the Venezuela&rsquo;s government and is being designed for the period of 2021-2026.&nbsp;</p>\n<p>Under the terms of the agreement, the new production will be located at the site of Venezuelan biotechnology firm Espromed Bio site, with which Geropharm established production links back in 2019. The production will be carried in the form of a finished dosage form.&nbsp;&nbsp;</p>\n<p>In addition to investments, Geropharm will transfer the know-how for the production of finished insulin preparations to its Venezuelan partners. In addition, the company will also continue to supply insulin analogs from Russia.</p>\n<h2><strong>Venezuela&rsquo;s govt to guarantee purchases</strong><strong>&nbsp;</strong></h2>\n<p>In the meantime, the Venezuelan government, from its side, will provide the company all the needed assistance during implementation of the project and guarantee the purchase of insulin preparations for the next five years - until 2026.&nbsp;</p>\n<p>According to official statistics, currently more than 2.96 million people suffer from diabetes in Venezuela. The needs of the country in insulin within the next five years are estimated at about 34 million packs. It is planned, the launch of the new project will allow to improve the situation with their treatment.&nbsp;</p>\n<p>Geropharm has been supplying insulin preparations to Venezuela on a regular basis since 2019. At the same time, there are no local producers. To date, Geropharm has already delivered over 3 million packages of drugs to the country.&nbsp;</p>\n<p>Geropharm is expected to be not the only Russian drugmaker planning to localize production in Venezuela and some other regional states, as, according to some Russian media reports, other pharmaceutical producers from Russia have similar plans.</p>", "date": "2021-04-06 12:02:00", "meta_title": "Russia\u00e2\u0080\u0099s pharma to accelerate expansion into Central and South America", "meta_keywords": "Genopharm, Production, Insulin, Venezuela, Espromed Bio", "meta_description": "Russia\u00e2\u0080\u0099s pharma to accelerate expansion into Central and South America", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-06 12:01:27", "updated": "2021-04-06 13:42:24", "access": NaN, "url": "https://www.thepharmaletter.com/article/russia-s-pharma-to-accelerate-expansion-into-central-and-south-america", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "geropharm-big.jpg", "image2id": "geropharm-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Diabetes", "topic_tag": "Focus On, From our correspondent, In Depth, Production, Russian market", "geography_tag": "Central America, Russia, South America, Venezuela", "company_tag": "Espromed Bio, Geropharm", "drug_tag": "Insulin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-06 12:02:00"}